Danish biotech firm Genmab's nine-month revenue up on higher royalties and product sales

Genmab A/S

05/11/2026 16:10

Overview
Denmark biotech firm's nine-month revenue rose 22% yr/yr, driven by higher royalties and product sales
Adjusted operating profit for nine months grew, reflecting investment in pipeline and commercialization
Company cites recent approvals and positive late-stage trial results for key oncology assets

Outlook
Genmab is maintaining its 2026 financial guidance published August 6, 2026

Result Drivers
ROYALTY REVENUE - Higher royalties from DARZALEX and Kesimpta drove revenue growth
PRODUCT SALES - Increased EPKINLY/TEPKINLY net product sales contributed to revenue rise
PIPELINE INVESTMENT - Higher operating expenses mainly reflected investment in product pipeline and commercialization capabilities

Company press release: ID:nGNEbWbwmq

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
9M Operating Expenses
 
$2.02 bln
 
9M Operating Profit
 
$986 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Genmab A/S is DKK4,050.00, about 13.2% above its November 4 closing price of DKK3,578.00
The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 20 three months ago

Reuters Recommended Reads
Nov 4 - Novo Nordisk Q3 adjusted profit, sales jump on GLP-1 demand; raises outlook
Nov 4 - Royalty Pharma Q3 adjusted EBITDA beats estimates; raises 2026 guidance
Nov 3 - Amgen Q3 revenue beats expectations on higher volumes

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)